Northern Trust’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $239K | Sell |
108,274
-12,710
| -11% | -$33.2K | ﹤0.01% | 3876 |
|
|
2026
Q1 | $283K | Hold |
120,984
| – | – | ﹤0.01% | 3819 |
|
|
2025
Q4 | $282K | Sell |
120,984
-8,659
| -7% | -$20.1K | ﹤0.01% | 3855 |
|
|
2025
Q3 | $244K | Buy |
129,643
+28,812
| +29% | +$63.4K | ﹤0.01% | 3914 |
|
|
2025
Q2 | $292K | Sell |
100,831
-93
| -0.1% | -$134 | ﹤0.01% | 3812 |
|
|
2025
Q1 | $72.7K | Buy |
100,924
+14,477
| +17% | +$12.2K | ﹤0.01% | 4168 |
|
|
2024
Q4 | $89K | Sell |
86,447
-25,050
| -22% | -$29.8K | ﹤0.01% | 4176 |
|
|
2024
Q3 | $149K | Sell |
111,497
-806
| -0.7% | -$1.08K | ﹤0.01% | 3963 |
|
|
2024
Q2 | $146K | Sell |
112,303
-2,256
| -2% | -$3.4K | ﹤0.01% | 3954 |
|
|
2024
Q1 | $197K | Buy |
114,559
+25,678
| +29% | +$40.3K | ﹤0.01% | 3900 |
|
|
2023
Q4 | $131K | Hold |
88,881
| – | – | ﹤0.01% | 4044 |
|
|
2023
Q3 | $108K | Buy |
88,881
+136
| +0.2% | +$188 | ﹤0.01% | 3994 |
|
|
2023
Q2 | $129K | Buy |
88,745
+2,489
| +3% | +$4.26K | ﹤0.01% | 3968 |
|
|
2023
Q1 | $125K | Buy |
86,256
+16,672
| +24% | +$27.9K | ﹤0.01% | 4025 |
|
|
2022
Q4 | $120K | Sell |
69,584
-379
| -0.5% | -$708 | ﹤0.01% | 4033 |
|
|
2022
Q3 | $140K | Sell |
69,963
-5
| -0% | -$5 | ﹤0.01% | 4011 |
|
|
2022
Q2 | $52K | Sell |
69,968
-168,484
| -71% | -$490K | ﹤0.01% | 4403 |
|
|
2022
Q1 | $2.07M | Sell |
238,452
-14,748
| -6% | -$151K | ﹤0.01% | 3080 |
|
|
2021
Q4 | $4.05M | Sell |
253,200
-4,739
| -2% | -$75.3K | ﹤0.01% | 2818 |
|
|
2021
Q3 | $4.75M | Sell |
257,939
-2,947
| -1% | -$47.3K | ﹤0.01% | 2767 |
|
|
2021
Q2 | $3.64M | Buy |
260,886
+21,308
| +9% | +$298K | ﹤0.01% | 3029 |
|
|
2021
Q1 | $3.53M | Sell |
239,578
-26,395
| -10% | -$465K | ﹤0.01% | 2957 |
|
|
2020
Q4 | $5.16M | Buy |
265,973
+54,896
| +26% | +$856K | ﹤0.01% | 2664 |
|
|
2020
Q3 | $2.36M | Buy |
211,077
+1,160
| +0.6% | +$13.7K | ﹤0.01% | 2984 |
|
|
2020
Q2 | $2.84M | Buy |
209,917
+46,643
| +29% | +$524K | ﹤0.01% | 2838 |
|
|
2020
Q1 | $1.32M | Buy |
163,274
+27,277
| +20% | +$240K | ﹤0.01% | 3073 |
|
|
2019
Q4 | $1.31M | Buy |
135,997
+15,913
| +13% | +$172K | ﹤0.01% | 3306 |
|
|
2019
Q3 | $1.27M | Buy |
120,084
+26,334
| +28% | +$278K | ﹤0.01% | 3311 |
|
|
2019
Q2 | $1.08M | Buy |
93,750
+5,416
| +6% | +$65.2K | ﹤0.01% | 3334 |
|
|
2019
Q1 | $1.13M | Sell |
88,334
-8,499
| -9% | -$90.2K | ﹤0.01% | 3315 |
|
|
2018
Q4 | $595K | Buy |
96,833
+1,038
| +1% | +$8.41K | ﹤0.01% | 3515 |
|
|
2018
Q3 | $1.01M | Buy |
95,795
+29,145
| +44% | +$338K | ﹤0.01% | 3468 |
|
|
2018
Q2 | $978K | Buy |
66,650
+291
| +0.4% | +$3.72K | ﹤0.01% | 3458 |
|
|
2018
Q1 | $945K | Buy |
66,359
+1,234
| +2% | +$15K | ﹤0.01% | 3392 |
|
|
2017
Q4 | $765K | Buy |
+65,125
| New | +$799K | ﹤0.01% | 3472 |
|
Other funds holding SPRO
GP
P
VCM
AI
VFT
GCP
Northern Trust's SPRO Position: Q2 2026 in Review
Northern Trust reduced its Spero Therapeutics (SPRO) stake by 11% in Q2 2026, selling an estimated $33.2K and leaving 108,274 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #3876.
Northern Trust first reported a position in SPRO in Q4 2017 and has held it in 35 quarters since. The position peaked at $5.16M in Q4 2020. 34 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.
- Northern Trust held 108,274 shares of Spero Therapeutics worth $239K as of Q2 2026.
- Northern Trust sold 12,710 Spero Therapeutics shares in Q2 2026, an estimated $33.2K.
- Spero Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3876 holding.
- Northern Trust first reported a position in Spero Therapeutics in Q4 2017 and has held it in 35 quarters since.
- Northern Trust's Spero Therapeutics position peaked at $5.16M in Q4 2020.
- 34 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.